Taiga Biotechnologies, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 2006-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.taigabiotech.com
Safety and Early Efficacy Study of TBX-2400 in Patients With AML or Myelofibrosis
Phase 1
Not yet recruiting
- Conditions
- Acute Myelogenous LeukemiaMyelofibrosis
- Interventions
- Biological: TBX-2400
- First Posted Date
- 2021-01-14
- Last Posted Date
- 2022-05-03
- Lead Sponsor
- Taiga Biotechnologies, Inc.
- Target Recruit Count
- 10
- Registration Number
- NCT04709458
- Locations
- 🇮🇹
Fondazione Policlinico Universitario Agostino Gemelli, Roma, Italy
🇭🇷University Hospital Centre Zagreb, Zagreb, Croatia
Study of TBX-3400 in Subjects With Solid Malignant Tumors Resistant or Refractory to Standard Therapies
Phase 1
- Conditions
- Tumor, SolidCancerRefractory Cancer
- Interventions
- Biological: TBX-3400
- First Posted Date
- 2020-11-23
- Last Posted Date
- 2022-02-02
- Lead Sponsor
- Taiga Biotechnologies, Inc.
- Target Recruit Count
- 60
- Registration Number
- NCT04640246
- Locations
- 🇮🇱
Rabin Medical Center, Petach Tikva, Israel
🇺🇸The Angeles Clinic and Research Institute, Los Angeles, California, United States
Study of TBX-3400 in Patients With Stage III and IV Melanoma Resistant or Refractory to Immune Checkpoint Inhibitors
Phase 1
Recruiting
- Conditions
- Stage IV MelanomaStage III Melanoma
- Interventions
- Biological: TBX-3400
- First Posted Date
- 2017-12-28
- Last Posted Date
- 2022-05-03
- Lead Sponsor
- Taiga Biotechnologies, Inc.
- Target Recruit Count
- 72
- Registration Number
- NCT03385486
- Locations
- 🇺🇸
University of Colorado Cancer Center, Denver, Colorado, United States
🇺🇸The Angeles Clinic and Research Institute, Los Angeles, California, United States
Safety and Early Efficacy Study of TBX-1400 in Patients With Severe Combined Immunodeficiency
Phase 1
- Conditions
- Severe Combined Immunodeficiency
- Interventions
- Biological: TBX-1400
- First Posted Date
- 2016-08-09
- Last Posted Date
- 2020-10-08
- Lead Sponsor
- Taiga Biotechnologies, Inc.
- Target Recruit Count
- 8
- Registration Number
- NCT02860559
- Locations
- 🇮🇱
Hadassah Medical Center (Ein Kerem site), Jerusalem, Israel
🇮🇱Schneider Children's Medical Center, Petach Tikva, Israel
© Copyright 2025. All Rights Reserved by MedPath